12:09 PM EDT, 06/03/2024 (MT Newswires) -- Gilead Sciences' ( GILD ) Kite unit said Monday that the phase 1/2 study assessing CAR T-cell therapy Tecartus in adults with relapsed or refractory B-cell acute lymphoblastic leukemia showed a median overall survival of 25.6 months and a four-year overall survival rate of 40% in all treated patients.

"Notably, Tecartus numerically improved overall survival particularly for patients when given in earlier lines of therapy," said Kite Vice President for Medical Affairs Ibrahim Elhoussieny.

Separately, Kite said a pilot study conducted together with the Dana-Farber Cancer Institute showed that Yescarta is well-tolerated in patients with relapsed or refractory primary or secondary central nervous system lymphoma.

Kite said the findings also suggest a trend in efficacy, with median progression-free survival and durability of response of more than a year.

Yescarta and Tecartus are available only through a restricted program under the Yescarta and Tecartus Risk Evaluation and Mitigation Strategy program, according to Kite.

Price: 63.66, Change: -0.61, Percent Change: -0.95